Table 2.
Summary of in Vitro and in Vivo Phenotypes for Pten/TP53 Null Prostatic Carcinoma Clonal Cell Lines
|
In Vitro |
In Vivo |
||||
|---|---|---|---|---|---|
| Clone | CK5 | CK8 | Vimentin | Tumor no. | Subcutaneous tumor phenotype |
| 1 | 75% | 100% | ND | 101 | Basal/squamous > adeno |
| 2 | 5% | 100% | ND | 301 | Sarcomatoid/undiff/adeno > basal/squamous |
| 3 | 37% | 100% | <1% | 211 | Basal/squamous > adeno |
| 4 | 90% | 100% | ND | 211 | Basal/squamous > adeno |
| 5 | 75% | 100% | <1% | 211 | Sarcomatoid > basal/squamous > adeno |
| 6 | 75% | 100% | <1% | 222 | Sarcomatoid |
| 7 | 62% | 75% | <1% | 222 | Adeno |
| 8 | 100% | 0% | ND | 222 | No tumor growth |
| 9 | 62% | 100% | ND | 222 | No tumor growth |
Average percentage of cells expressing CK5, CK8, and vimentin determined by counting at least 200 cells per clonal cell line.
Adeno, adenocarcinoma; Basal/squamous, basal/squamous carcinoma; ND, not detected (no cells detected expressing the marker in the entire well of an 8-well chamber slide containing approximately 1800 cells); Undiff, undifferentiated carcinoma; <1%, less than 10 cells expressing the marker in the entire well of the chamber slide containing approximately 1800 cells.